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A historical perspective on the discovery of statins
By Akira ENDO*1,†
(Communicated by Teruhiko BEPPU, M.J.A.)
Abstract: Cholesterol is essential for the functioning of all human organs, but it is
nevertheless the cause of coronary heart disease. Over the course of nearly a century of
investigation, scientists have developed several lines of evidence that establish the causal connection
between blood cholesterol, atherosclerosis, and coronary heart disease. Building on that knowledge,
scientists and the pharmaceutical industry have successfully developed a remarkably eﬀective class
of drugs—the statins—that lower cholesterol levels in blood and reduce the frequency of heart
attacks.
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Since it was ﬁrst isolated from gallstones in 1784,
cholesterol has fascinated scientists from many areas
of science and medicine. Thirteen Nobel Prizes have
been awarded to scientists who devoted major parts
of their careers to cholesterol research1) French
physician-chemist François Poulletier was the ﬁrst
to obtain pure cholesterol from gallstones. Some
thirty years later, French chemist Michel E. Chevreul
named it cholesterine (solid bile in Greek: chole for
bile and stereos for solid). The exact molecular
formula of cholesterol was accurately established in
1888 by Austrian botanist Friedrich Reinitzer.2) The
cholesterol molecule has four rings, and this tetra-
cyclic skeleton made it extremely challenging to
elucidate its structure, which occupied scientists for
a good part of the ﬁrst quarter of the twentieth
century. Proof of the structure of cholesterol was
obtained chieﬂy through the brilliant work of
Heinrich O. Wieland and Adolf Windaus. They won
the Nobel Prize in Chemistry in 1927 and 1928,
respectively, for their cholesterol work.1)
Milestones on the road to
the development of the statins
Animal models in atherosclerosis. During the
19th century, arteriosclerosis was well recognized,
but its etiological and pathological signiﬁcance had
not been established. The hypotheses explaining it
ranged from disturbed arterial metabolism to adher-
ent blood clots that gradually changed into arterio-
sclerotic plaques. The ﬁrst hint that cholesterol was
related to atherosclerosis goes back to 1910, when
Windaus reported that atherosclerotic plaques from
aortas of human subjects contained over 20-fold
higher concentrations of cholesterol than did normal
aortas.3) Three years later, the Russian pathologist
Nikolai Anitschkow fed pure cholesterol to rabbits,
which produced marked hypercholesterolemia and
severe atherosclerosis of the aorta.4) This was the ﬁrst
experimental production of atherosclerosis. At that
time, however, his ﬁndings were largely rejected or at
least not followed up. Serious research on the role of
cholesterol in human atherosclerosis did not really
get underway until the 1940s, due to a prevailing
view that the disease was a simple consequence of
aging and could not be prevented.
Genetic connection. The genetic connection
between cholesterol and heart attacks was ﬁrst made
in 1939 by Norwegian clinician Carl Müller, who
described several large families in which high blood-
cholesterol levels and premature heart attacks
together were an inherited trait. In the mid-1960s,5)
the genetic understanding of this syndrome, which
came to be known as familial hypercholesterolemia
(FH), was more extensively studied by Avedis K.
Khachadurian,6) He delineated two clinically distinct
forms of FH in inbred families—the homozygous
form, in which aﬀected individuals manifest severe
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terol levels of about 800mg/dl) and heart attacks
that occur as early as 5 years of age, and the
heterozygous form, characterized by levels in the 300-
to 400-mg/dl range and premature heart attacks that
occur typically between 35 and 60 years of age. In
addition to studies with animal models, the genetic
studies strongly suggested a causal relationship
between cholesterol and atherosclerosis and coronary
heart disease.
Epidemiologic studies. In the early 1950s,
the epidemiologic study of the cholesterol-coronary
connection was unfolded by John Gofman at the
University of California at Berkeley, who used the
newly developed ultracentrifuge to separate plasma
lipoproteins by ﬂotation. Gofman found not only that
heart attacks correlated with elevated levels of blood
cholesterol but also that the cholesterol was con-
tained in low density lipoprotein (LDL). He also
observed that heart attacks were less frequent when
the blood contained elevated levels of high density
lipoprotein (HDL).7)–9)
The epidemiologic connection between blood
cholesterol and coronary atherosclerosis was ﬁrmly
established by a physiologist at the University of
Minnesota, Ancel Keys, whose Seven Countries
Study (beginning in the mid-1960s) showed that
the incidence of heart attacks in 15,000 middle-aged
men followed for 10 years was linearly proportional to
the blood level of cholesterol.10)–12) The Framingham
Heart Study was carried out by the National Heart
Institute in Framingham, Ma. It provided the ﬁrst
solid and unarguable evidence that individuals with
higher blood cholesterol levels at the time of the
baseline examination were more likely to experience a
myocardial infarction in the subsequent years of
follow-up. It also showed that the risk was increased
by a number of other factors such as high blood
pressure and smoking.13),14)
Cholesterol biosynthetic pathway. The
clinical interest in cholesterol led to an intense eﬀort
in the 1950s to determine the pathway by which
cholesterol was synthesized in the body. Most of the
crucial steps in this complex pathway, involving
30 enzymatic reactions, were worked out by four
biochemists—Konrad E. Bloch, Feodor Lynen, John
Cornforth, and George Popják.15)–19) Cholesterol
synthesis takes place in four stages:
(1) condensation of three acetate units to form a six-
carbon intermediate, mevalonate; (2) conversion of
mevalonate to activated isoprene units; (3) polymer-
ization of six 5-carbon isoprene units to form the 30-
carbon linear squalene; (4) cyclization of squalene to
form the steroid nucleus, with a further series of
changes to produce cholesterol.
The third reaction in the ﬁrst stages is the
committed and rate-limiting step: reduction of HMG-
CoA to mevalonate is the major point of regulation
on the pathway to cholesterol (Fig. 1). The major
outlines of this pathway were completed by 1960, and
Bloch and Lynen were awarded the Nobel Prize in
1964.
At the Nobel Banquet in Stockholm, December
10, 1964 when Konrad Bloch and Feodor Lynen, were
awarded the Nobel Prize, S. Friberg, Rector of the
Caroline Institute, made the following remarks:
“Your discoveries may provide us with weapons
against some of mankind’s gravest maladies, above
all in relation to cardiovascular diseases. Achieve-
ments like yours make it not unrealistic to look
forward to a time, when mankind will not only live
under vastly improved conditions, but will itself be
better”.20)
Regulation of cholesterol metabolism. Reg-
ulation of cholesterol metabolism was extensively
studied by several scientists in the U.S. in the
1960s.21)–26) Cholesterol in the body can be derived
from what is absorbed from the diet and from what is
synthesized in the body, mainly by the liver. The
former type is supplemented by the latter if the
required levels are not met, but if the former type
of “exogenous” cholesterol reaches its required level,
the synthesis function of the liver is suppressed to
prevent excessive production of cholesterol. Feedback
suppression of cholesterol synthesis in the liver by
dietary cholesterol is mediated through changes in
the activity of HMG-CoA reductase that catalyzes
the conversion of HMG-CoA to mevalonate Changes
in reductase activity are closely related to changes in
the overall rate of cholesterol synthesis. In humans,
cholesterol produced in the liver exceeds what is
absorbed from the diet, even when a large quantity of
cholesterol is ingested. These ﬁndings suggest that
the inhibition of HMG-CoA reductase would be an
eﬀective means of lowering plasma cholesterol in
humans.
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Fig. 1. HMG-CoA reductase reaction.
Discovery of statins No. 5] 485Searching for cholesterol synthesis inhibi-
tors. As evidence grew that high blood cholesterol
levels were linked to heart disease, scientists in both
academia and industry began searching for drugs
to lower blood cholesterol. In the 1950s and 1960s,
many companies were searching for molecules that
would block one of the 30 steps in the synthesis of
cholesterol from acetyl-coenzyme A (CoA). Many
molecules homologous to intermediates along the
pathway were synthesized. Some molecules were
eﬀective in animals, but none of those were eﬀective
at the clinical level.27) Triparanol(MER/29), which
was introduced into clinical use in the U.S. in 1959,
was the ﬁrst cholesterol-lowering agent that inhibited
cholesterol synthesis. However, it was withdrawn
from the market in the early 1960s because of serious
side eﬀects, including cataracts.28)–31) Triparanol
inhibited the ﬁnal stage in the cholesterol synthetic
pathway, resulting in the accumulation of other
sterols.
Cholesterol-lowering agents available in the
1960s. The cholesterol-lowering properties of
nicotinic acid were discovered in 1955 by Canadian
pathologist Rudolf Altschul.32) At that time, nico-
tinic acid was the only drug eﬀective in lowering
both cholesterol and triglycerides. Cloﬁbrate was
synthesized at Imperial Chemical Industries (ICI) in
England and marketed in 1958.33) In the 1960s, many
derivatives of cloﬁbrate, called ﬁbrates, that were
more potent and safer than cloﬁbrate were devel-
oped. In most patients, the cholesterol-lowering
eﬀect of ﬁbrates was minimal to moderate. Details
of their actions at the biochemical level were not well
understood.34) Cholestyramine, an anion-exchange
resin, acts by binding bile acids within the intestinal
lumen, thus interfering with their reabsorption and
enhancing their fecal excretion.35),36) Cholestyramine
is highly eﬀective in the treatment of many patients
with hypercholesterolemia, but unfortunately, it is
not tolerated by all patients.34) Therefore, none of
these agents could be considered ideal in terms of
eﬃcacy or safety.
Birth of the statins
I (Akira Endo) was born into a rural farming
family in northern Japan, in Akita, where I lived for
17 years with my extended family, including my
grandparents. My grandfather, who had an interest
in medicine and science, was a great home teacher to
me. Thanks to his inﬂuence, I became fascinated with
mushrooms and other molds, and at the age of 10, I
dreamt of becoming a scientist, much like renowned
Japanese scientist Hideyo Noguchi, who, in 1900 at
the age of 24, went to the United States and studied
syphilis and yellow fever at the Rockefeller Institute
in New York.37),38)
The antibiotic era. After ﬁnishing high school
in Akita, I entered Tohoku University’s College of
Agriculture in Sendai, where I was inspired by the
biography of Alexander Fleming, who discovered
penicillin in the blue-green mold belonging to the
genus Penicillium in 1928.39) A decade later, pen-
icillin was developed as a systemic therapeutic agent
by a research group at Oxford University headed
by Florey, Chain and Abraham. In 1940, Selman
Waksman isolated streptomycin, an antibiotic active
against the tubercle bacillus, from Streptomyces
griseus.40) Since then, many antibiotics have been
isolated from a variety of microorganisms. At that
time, many drug companies and universities in Japan
were conducting active research and development
in ﬁnding eﬀective antibiotics. As a result, I was
deeply impressed by the knowledge that antibiotics
had saved the lives of many patients with infectious
diseases.
Upon graduating in 1957, I joined the pharma-
ceutical company Sankyo in Tokyo, where I was
assigned to one of the applied microbiology groups.
I worked toward developing a new pectinase that
hydrolyzed viscid pectin contaminated wines and
ciders. In 1958, I found a grape-parasitic fungus,
Coniothyrium diplodiella, to be a potent producer of
such an enzyme. One year later, this new enzyme was
commercialized. I then puriﬁed it and elucidated its
properties.41)–44)
Study in the US. At this point, I became
interested in cholesterol biosynthesis. Towards the
end of 1965, I wrote a letter to Konrad Bloch, who
had received the Nobel Prize for his research on
cholesterol biosynthesis in 1964,15) expressing my
wish to study under him. Unfortunately, the autumn
1966 class for which I was applying was already full.
So I eventually worked on the role of phospholipids
in an enzyme system involved in the synthesis of
bacterial cell wall lipopolysaccharides in the depart-
ment of a great biochemist, Bernard Horecker, at the
Albert Einstein College of Medicine in New York
City for 2 years, from 1966 to 1968.45),46)
While living in New York, I was very surprised
by the large number of elderly and overweight people,
and by the rather rich dietary habits of Americans
compared to those of the Japanese. In the residential
area of the Bronx where I lived, there were many
elderly couples living by themselves and I often saw
A. ENDO [Vol. 86, 486ambulances going to take an elderly person who had
suﬀered a heart attack to the hospital. At that time,
coronary heart disease was the main cause of death
in the United States. The number of patients with
hypercholesterolemia, a precursor to coronary heart
disease, was said to exceed 10 million.
How to search for HMG-CoA reductase
inhibitors. After coming back to Tokyo in 1968,
Sankyo Research Laboratories gave me an opportu-
nity to work on a project of my own choosing.
Antibiotics were shown to inhibit many diﬀerent
kinds of enzymes, not only in bacterial cells but also
in mammalian cells.47) Although no metabolites that
inhibited any enzymes involved in cholesterol syn-
thesis had been isolated previously, I speculated that
fungi like molds and mushrooms would produce
antibiotics that inhibited HMG-CoA reductase.
Inhibition of HMG-CoA reductase would thus be
lethal to these microbes.
At that time, HMG-CoA reductase was assayed
principally by measuring the incorporation of radio-
activity from [14C]HMG-CoA into mevalonate.48) As
[14C]HMG-CoA was too expensive to use for deter-
mining the inhibitory activity of thousands of sam-
ples, we ﬁrst searched for microbial culture broths
that inhibited the incorporation of [14C]acetate into
nonsaponiﬁable lipids.49) The active broths were
then tested for their ability to inhibit lipid synthesis
from [3H]mevalonate. Culture broths that were active
in the ﬁrst assay but not active in the second
determination were suspected to contain a compound
(or compounds) that inhibited the early stages
between acetate and mevalonate in the cholesterol
synthetic pathway. The principal active compo-
nent(s) in these culture broths were then isolated.
Rat liver enzymes were used for these assays.50)
Isolation of citrinin. Inspired by Fleming’s
success with molds, we began our project using
culture broths of thousands of fungi in April 1971,
and one year later, after 3800 strains of fungi, we
found that a culture broth of mold showed potent
inhibitory activity. The active principle turned out to
be a known substance—citrinin.51) Citrinin strongly
inhibited HMGCoA reductase and, furthermore,
lowered serum cholesterol levels in rats.51),52) How-
ever, the research was suspended because of its
toxicity to the kidneys. Nevertheless, the experience
with citrinin gave us hope and courage that we might
be able to discover much better active substances in
the near future.
Discovery of compactin (ML-236B). In the
mid-summer of 1972, We found a second active
culture broth of blue-green mold, Penicillium cit-
rinum Pen-51, which was isolated from a rice sample
collected at a grain shop in Kyoto. This mold is
similar to the blue-green molds that contaminate
fruits, like oranges and melons. It took us one year to
isolate the active principles from the culture broth,
mainly because of the very low productivity of active
compounds. Finally, in July 1973, we were able to
isolate three active metabolites from the culture
broth by solvent extraction, silica gel chromatogra-
phy, and crystallization.53)–55) These metabolites
showed potent activity to inhibit cholesterol syn-
thesis both in vitro and in vivo.56) The most active
product of these three, called ML-236B, was used to
further developmental study. ML-236B, for historical
reasons discussed later, was referred to in the early
years as compactin and the name stuck. I shall
continue to refer to it that way in this review.
HMG-CoA reductase is the rate-controlling
enzyme in cholesterol synthesis. We soon realized
the structural similarities between compactin and
HMG-CoA, the substrate of the HMG-CoA reduc-
tase reaction55),57) (Fig. 2). The structure of compac-
tin was exactly as we had previously envisioned.
Compactin was an extremely potent inhibitor of
HMG-CoA reductase, and its mechanism of action,
as suggested by its structure, was that of a
competitive inhibitor.57) I had set my sights on
ﬁnding a competitive inhibitor of HMG-CoA reduc-
tase, and compactin seemed to be a wonderful gift
from nature.
Inhibition of sterol synthesis in cultured
cells. In 1973, Michael Brown and Joseph Goldstein
demonstrated that in cultured ﬁbroblasts of patients
with familial hypercholesterolemia (FH),58),59) regu-
lation of HMG-CoA reductase was partially or
completely lost, resulting in high reductase activity
O
O
O
O
O
OH
O
O
O-
H
H
HO HO
Two forms of compactin
Lactone form Acid from
HMG-CoA
O
COOH
H3C
S-CoA
HO
H
H
Fig. 2. Structual similarities between compactin and HMG-
CoA.
Discovery of statins No. 5] 487even in the presence of low-density lipoprotein
(LDL). As expected, compactin strongly inhibited
sterol synthesis from acetyl-CoA in a variety of
cultured mammalian cells and worked just as well in
cells with patients with familial hypercholesterolemia
as it did in normal cells. Inhibition was 50% at as low
as 0.4ng/ml (10−9M) in both types of cell.60)
At very high concentrations, at which sterol
synthesis and HMG-CoA reductase were strongly
inhibited, cells were not able to grow and died, even
in the presence of lipoproteins. But, this inhibition
was overcome and cells grew normally by adding a
small amount of mevalonate, the product of the
HMG-CoA reductase reaction,60) indicating that
inhibition by compactin was very speciﬁc to HMG-
CoA reductase. In 1976 we published two papers
reporting the discovery and characterization of
compactin, the ﬁrst statin.53),57)
In 1978, in collaboration with my group at
Sankyo, Brown and Goldstein, adding compactin to
cultured human cells, homogenized the cells and
measured HMG-CoA reductase activity in vitro.
They found a large increase in the amount of enzyme
activity. Apparently, the cells tried to produce more
of the enzyme. The enzyme was inactive in the cell
because compactin was present. When the cells were
homogenized, the compactin was diluted and the
latent enzyme activity became apparent.61),62)
Compactin does not work in rats. The next
chapter in the statin story involved a series of animal
experiments to determine the eﬃcacy and toxicity of
compactin. In 1974, biologists at Sankyo evaluated
the eﬃcacy of compactin by feeding rats a diet
supplemented with compactin for 7 days. Unfortu-
nately, there was no reduction in serum cholesterol.55)
With these results, there was no hope of
convincing the biologists of evaluating compactin,
which did not work in rats, in other animal species
like dogs and monkeys. It looked as if 2 years of work
and over 6,000 tests had led nowhere. Fortunately,
although Sankyo Co. was not keenly interested in
developing cholesterol lowering drugs, they permit-
ted the project to continue.
We spent the next two years trying to elucidate
the mechanism of action of compactin and the reason
why it was not eﬀective in rats. These experiments
showed that while compactin did not work in rats
when given repeatedly for 7 days, it was eﬀective in
lowering serum cholesterol levels in the animals
between 3 to 8 hours after a single dose. However,
after 8 hours, hepatic HMG-CoA reductase activity
of rats was induced. When given repeatedly, com-
pactin increased the amount of hepatic HMG-CoA
reductase 8- to 10-fold and thereby cancelled out the
inhibition of sterol synthesis by compactin.63) This
induction was found to be the main reason why
compactin did not work in rats. These ﬁndings
suggested that compactin would be eﬀective in other
animal species and patients with elevated blood
cholesterol levels.
Compactin was highly eﬀective in hens, dogs
and monkeys. To move the compactin project on, it
was essential to show that compactin was active in
lowering plasma cholesterol in experimental animals.
In the early spring of 1976, Noritoshi Kitano, a
pathologist at Sankyo who was keeping laying
hens for research purposes, kindly agreed to a joint
research project to evaluate compactin using his
hens. The experiments were a great success. The
plasma cholesterol of laying hens that received
compactin decreased by 50% after one month
(unpublished results). We were also able to conﬁrm
the profound cholesterol-lowering eﬀects of compac-
tin in dogs64) and monkeys.65)
These results deﬁned compactin as a candidate
for a new type of drug. So, the ‘Compactin Develop-
ment Project’—headed by myself and including
pharmacologists, pathologists, toxicologists, organic
chemists and microbiologists—was launched in Au-
gust 1976.
Interestingly, at around the same period, re-
searchers from England’s Beecham Pharmaceuticals,
now known as GlaxoSmithKline, had also discovered
compactin as an antifungal agent from another blue-
green mold (Penicillium brevicompactum).66) How-
ever, they were unable to develop compactin as a
cholesterol-lowering agent due to its inability to
lower the blood cholesterol of rats as consistent with
our results.67)
Second challenge. We encountered a second
challenge in April 1977, just 8 months after the
launch of the Compactin Development Project. The
issue was the detection of microcrystalline structures
in the liver cells of rats that had been fed extremely
large amounts of compactin (more than 500 milli-
grams per kilogram body weight per day (mg/kg/d)
for 5 weeks. The toxicologists insisted that these
structures were toxic substances. It took us 9 months
to identify these microcrystalline structures as non-
toxic cholesterol.
Treatment of patients with severe hyper-
cholesterolemia. The success of our studies led us
to a clinical study in patients that was not sanctioned
by Sankyo. Since I am not a physician, I performed
A. ENDO [Vol. 86, 488this study in collaboration with Akira Yamamoto, a
physician at the Osaka University Hospital in Osaka.
In February 1978, Yamamoto started treating an 18-
year old woman with severe familial hypercholester-
olemia. Her serum cholesterol dropped from 1,000mg
per deciliter to ³700mg per deciliter during treat-
ment with compactin at a daily dose of 500mg.68) But
after treatment for 2 weeks, trans-aminase levels of
blood were elevated, and muscular dystrophy was
observed. Both adverse eﬀects were reversible on
discontinuation of treatment. While cholesterol levels
of the patient were not reduced as expected, tuberous
and Achilles tendon xanthomatosis was markedly
reduced after treatment at 200mg of compactin for 5
months.
In the following 6 months, Yamamoto treated
ﬁve heterozygous patients with familial hypercholes-
terolemia and three patients with combined hyper-
lipidemia with compactin, and their cholesterol
declined by roughly 30% on average; no severe side
eﬀects were noted. We published these studies in a
medical journal in 1980.68)
These treatments led to the clinical development
of compactin at Sankyo. In November 1978, Sankyo
started a phase 1 clinical trial for compactin. In phase
2 of the trial, started in the summer of 1979,
compactin was administered to subjects with serious
cases of hypercholesterolemia at twelve hospitals. All
of the participating hospitals reported positively on
the remarkable eﬃcacy and excellent safety proﬁle of
compactin.69)
Discontinuation of compactin development.
In August 1980, however, Sankyo discontinued the
clinical development of compactin, which had been
progressing smoothly until that time. Since then,
compactin has never come back. It was said that the
drug caused lymphoma in dogs that received aston-
ishingly high doses, 100 or 200mg/kg/day for 2
years. No abnormalities were noted in the group
receiving 20mg/kg/day (personal communications).
Yamamoto had already shown that compactin was
fairly eﬀective even in patients with severe hyper-
cholesterolemia at less than 1mg/kg/day.69) In other
words, the dogs were getting about 200 times the
dosage that would be used in patients. In the
development of the second statin, called pravastatin.
Sankyo avoided the same trouble by limiting its
maximum dose to 25mg/kg/day.70) So, regardless of
whether lymphomas were actually detected or not,
Sankyo could have continued the development of
compactin by limiting its maximum dose to 25mg/
kg/day.
Development of lovastatin
Discovery of lovastatin. At the end of the
1970s, the ﬁndings showing the dramatic eﬀects of
compactin in dogs and monkeys inspired many
pharmaceutical companies to begin searching for
another statin. Merck was ﬁrst out of the gate. In
July 1976, Roy Vagelos, President of Merck Research
Laboratories, signed a conﬁdentiality agreement with
Sankyo and obtained samples of compactin and our
conﬁdential experimental data. Merck researchers
conﬁrmed our ﬁndings and were astonished at the
potency of the drug. Under the direction of Alfred
Albert, Merck set out to ﬁnd its own statins and in
February 1979 isolated a statin very similar to
compactin in chemical structure, called mevinolin,
from the fungus Aspergillus terreus.71)–73)
At the end of 1978, I left Sankyo and moved
to Tokyo Noko University (Tokyo University of
Agriculture and Technology), where I continued my
work on reductase inhibitors, and in February 1979
isolated another statin (named monacolin K) from
cultures of Monascus ruber.74) In the fall of the
same year, it was conﬁrmed that monacolin K and
mevinolin were the same compound (later both
changed to lovastatin) (Fig. 3).
Suspension of lovastatin development.
Merck began preliminary clinical studies of lovastatin
in April 1980 but after 5 months, in September
1980, they discontinued the clinical trials because of
rumors that the closely related compound, compac-
tin, caused certain cancers in dogs. They could not
ignore the rumors and it appeared that the lovastatin
project was dead.72),73)
In early 1981, Brown and Goldstein reported
that lovastatin could raise liver LDL receptors in
dogs, and this led to a profound fall in plasma LDL
levels.75) Lovastatin was then tested on people, and it
was shown to produce a profound fall in plasma LDL
levels.76)
Seven months later, Hiroshi Mabuchi’s group at
Kanazawa University reported the impressive results
of their highly successful compactin treatment of
severe heterozygous patients with familial hyper-
cholesterolemia.77) The LDL cholesterol, or bad
cholesterol, of these patients declined by an average
of 30% with no fall in HDL cholesterol, or good
cholesterol; rather, a slight increase was noted.
Subsequently, Mabuchi used a combination of com-
pactin and cholestyramine in patients with hetero-
zygous familial hypercholesterolemia. LDL choles-
terol was reduced by 50–60% by the combination.78)
Discovery of statins No. 5] 489Birth of the ﬁrst commercial statin. In July
1982, several clinicians stimulated by Mabuchi’s
report,77) including Roger Illingworth of Oregon
Health Sciences University and Scott Grundy and
David Bilheimer of the University of Texas, treated
patients with severe hypercholesterolemia unrespon-
sive to available agents.72),73) The drug showed
dramatic activity in lowering LDL cholesterol, with
very few side eﬀects. This led Merck to begin large-
scale clinical trials of lovastatin in patients at high
risk and long-term toxicity studies in dogs in 1984.
The drug dramatically reduced cholesterol levels and
was well tolerated. No tumors were detected. In
November 1986, Merck sent the New Drug Applica-
tion (NDA) to the U.S. FDA and lovastatin was
given FDA approval to become the ﬁrst commercial
statin in September 1987.72),73) Two years earlier, in
1985, Brown and Goldstein were awarded the Nobel
Prize in Physiology or Medicine for their discoveries
concerning the regulation of cholesterol metabo-
lism.1)
Conclusion
Since lovastatin had been commercialized, 6
statins, including 2 semi-synthetic statins (simvasta-
tin and pravastatin) and 4 synthetic statins (ﬂuvas-
tatin, atorvastatin, rosuvastatin and pitavastatin)
have been introduced to the market55),79) (Fig. 3).
Lovastatin was followed by a new statin, simvastatin.
Sankyo, in turn, developed pravastatin and launched
it in 1989. Four synthetic statins, shown in Fig. 3,
were subsequently developed. Today the most
popular statin is Pﬁzer’s atorvastatin (Lipitor®).
Statins have now been tested in many large-scale
clinical trials, involving 90,000 subjects who were
followed for 5 years.27),80),81) The results in all these
studies have been consistent: treatment with statins
lowers plasma LDL levels by 25–35% and reduces the
frequency of heart attacks by 25–30%. It is said that
the percentage reduction in coronary events would be
even more dramatic if the treatment were longer and
if statin therapy were started earlier. No major
adverse eﬀects of lowering cholesterol were noted in
any of the studies. The remarkable safety of statins
derives from their unique mechanism of action. The
statins are the largest selling class of drugs currently
taken by patients throughout the world. Sales for this
one class of drugs in 2005 were $25 billion.
Today, an estimated 30 million people world-
wide are taking statins. It is said that the lives of
millions of people have been extended through statin
therapy. I believe that the words Rector Friberg
spoke at the 1964 Nobel Prize Banquet—that we may
“look forward to a time when mankind will not only
live under vastly improved conditions, but will itself
be better”—have truly been realized.82)
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Proﬁle
Akira Endo, born in 1933, obtained a BA at Tohoku University (Faculty of
Agriculture) in Sendai in 1957 and a PhD in biochemistry at the same university in 1966.
From 1957 to 1978 he worked as a biochemist at Sankyo Co. He spent two years (1966–
1968) at the Albert Einstein College of Medicine in New York as a research associate.
From 1979 to 1997 he worked as an associate professor (1979–1986) and later a full
professor (1986–1997) at the Tokyo University of Agriculture and Technology (TUAT),
and after oﬃcial retirement, besides becoming the director of Biopharm Research
Laboratories Inc. (Tokyo), he serves as a professor on Special Mission at Tohoku
University and Waseda University and a Visiting Professor at Kanazawa University and
Hitotsubashi University. Prizes and honors received include the 1987 Heinrich Wieland
Prize (Germany), the 1987 Toray Science-Technology Prize (Japan), the 2000 Warren Alpert Foundation Prize
(U.S.A.), the 2006 Japan Prize, the 2006 Massry Prize (U.S.A.), the 2008 Albert Lasker³DeBakey Clinical Medical
Research Award (U.S.A.), Distinguished Professor Emeritus at TUAT (2008) Honorary Citizen of Akita
Prefecture, Japan (2008), Outstanding Achievement Award (2009, International Society of Atherosclerosis) and
the 2008 Lasker Awardee Special Lecture (American Heart Association).
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